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doi:10.1Objective: The effects of hydroxyethyl starch on bleeding after cardiopulmonary bypass were determined.
Methods: A meta-analysis was performed of postoperative blood loss in randomized clinical trials of hydrox-
yethyl starch versus albumin for fluid management in adult cardiopulmonary bypass surgery. Impacts of hydrox-
yethyl starch molecular weight and molar substitution were assessed. Randomized trials directly comparing
different hydroxyethyl starch solutions were also included.
Results: Eighteen trials with 970 total patients were included. Compared with albumin, hydroxyethyl starch in-
creased postoperative blood loss by 33.3% of a pooled SD (95% confidence interval, 18.2%–48.3%; P<.001).
Risk of reoperation for bleeding was more than doubled by hydroxyethyl starch (relative risk, 2.24; 95% con-
fidence interval, 1.14–4.40; P¼ .020). Hydroxyethyl starch increased transfusion of red blood cells by 28.4% of
a pooled SD (95% confidence interval, 12.2%–44.6%; P<.001), of fresh-frozen plasma by 30.6% (95% con-
fidence interval, 8.0%–53.1%; P ¼ .008), and of platelets by 29.8% (95% confidence interval, 3.4%–56.2%;
P ¼ .027). None of these effects differed significantly between hydroxyethyl starch 450/0.7 and 200/0.5. Insuf-
ficient data were available for hydroxyethyl starch 130/0.4 versus albumin; however, no significant differences
were detected in head-to-head comparisons of hydroxyethyl starch 130/0.4 with 200/0.5. Albumin improved he-
modynamics. There were no differences in fluid balance, ventilator time, intensive care unit stay, or mortality.
Conclusions:Hydroxyethyl starch increased blood loss, reoperation for bleeding, and blood product transfusion
after cardiopulmonary bypass. There was no evidence that these risks could be mitigated by lower molecular
weight and substitution. (J Thorac Cardiovasc Surg 2012;144:223-30)Supplemental material is available online.Excessive postoperative bleeding remains a frequent, seri-
ous, and unpredictable complication of cardiac surgery
with cardiopulmonary bypass (CPB) that can prompt trans-
fusion of blood products, delay extubation, necessitate re-
operation, and worsen outcome. CPB can result in
acquired transient platelet dysfunction attended by diffuse
nonsurgical postoperative bleeding. Choice of fluid for ex-
tracorporeal circuit priming and perioperative volume ex-
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Mbleeding. Common choices are colloids such as albumin
and hydroxyethyl starch (HES).
A 2001 meta-analysis of 16 randomized trials with 653
total patients undergoing surgery with CPB demonstrated
an increase in postoperative blood loss among patients re-
ceiving HES relative to albumin.1 A warning against the
use of HES in cardiac surgery because of increased bleeding
risk was thereafter required by the US Food and Drug Ad-
ministration on the prescribing information for HES of mo-
lecular weight 450 kDa and molar substitution 0.7 (HES
450/0.7) in saline solution.
Nevertheless, HES solutions continue to be advocated for
use in surgery with CPB. It has been postulated that HES so-
lutions of lower molecular weight and substitution could
carry less bleeding risk. Although randomized trial data
on the use of such solutions in cardiac surgery were limited
at the time of the 2001 meta-analysis, data have subse-
quently accumulated. This meta-analysis was designed to
test, in light of all currently available randomized trial
data, the null hypothesis that HES does not increase postop-
erative blood loss relative to albumin in patients undergoing
CPB. Prespecified subgroup analyses were performed to
evaluate potential differences in the effects on postoperative
blood loss of the 3 most commonly used HES solutions,
namely HES 450/0.7, HES 200/0.5, and HES 130/0.7. Pos-
sible differences in direct head-to-head randomized com-
parisons of these HES solutions were also assessed.rdiovascular Surgery c Volume 144, Number 1 223
Abbreviations and Acronyms
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
FFP ¼ fresh-frozen plasma
HES ¼ hydroxyethyl starch
ICU ¼ intensive care unit
RBC ¼ red blood cell
RR ¼ relative risk
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MMATERIALS AND METHODS
Selection Criteria
Randomized trials comparing HES 450/0.7, HES 200/0.5, or HES 130/
0.4 with albumin in adult patients undergoing CPB were eligible. Head-to-
head trials between any pairs of those 3 HES solutions could also be in-
cluded. Postoperative blood loss data had to be available. No language or
time period restrictions were applied. Trials were excluded if all patients
in one group crossed over to receive the other test colloid during the study
observation period, because such crossoverwould confound trial outcomes.
Trials of Boldt and coworkers were excluded in light of public disclosures
indicating scientific misconduct by those investigators (www.klilu.de/
content/aktuelles___presse/pressearchiv/2010/untersuchungsbericht_der_
kommission_fuer_die_pressekonferenz_am_29_november_2010/index_
ger.html?raw=Boldt&ZMS_HIGHLIGHT=raw).
End Points
The primary end point was cumulative blood loss during the first 24
hours after CPB. Secondary end points were reoperation for bleeding
and blood product transfusion during the first 24 postoperative hours. Ad-
ditional supplementary end points were fluid balance, hemodynamics, time
on ventilator, intensive care unit (ICU) stay, and mortality.
Search Methods
Published and unpublished trials were sought by computer searches of
MEDLINE; Embase; the Cochrane Library; ClinicalTrials.gov; the US
Food and Drug Administration and European Medicines Agency
web sites; and abstract databases for major conferences in surgery, anes-
thesiology, and intensive care. Search terms included the following: hy-
droxyethyl starch, HES, hetastarch, pentastarch, tetrastarch, albumin,
coronary artery bypass, bleeding, hemorrhage, blood transfusion, random-
ized controlled trial, and random allocation. Full-text Internet searches
with the Google search engine were also performed. Investigators in-
volved in fluid management for cardiac surgery and manufacturers of col-
loid products used in cardiac surgery were contacted as an aid in
identifying eligible trials. Reference lists of primary research papers and
review articles were consulted, and selected journals were searched by
hand or their online tables of contents were examined. Data on file at
US government agencies from eligible trials were requested under the
Freedom of Information Act.
Data Extraction
Two investigators (R.J.N. and M.M.W.) independently determined trial
eligibility and extracted data from the trial reports. Differences in interpre-
tation were resolved through discussion. The investigators, patients, and
methods in the trial reports were closely compared to avoid duplication.
Extracted data consisted of the numbers of patients; age; indication for fluid
administration; colloid regimen; type of HES solution; mean and SD of
postoperative blood loss; reoperation for bleeding; units of red blood cells
(RBCs), fresh-frozen plasma (FFP) and platelets transfused; cumulative
fluid balance; heart rate; cardiac index; mean arterial pressure; central224 The Journal of Thoracic and Cardiovascular Surgvenous pressure; pulmonary capillary wedge pressure; time on ventilator;
ICU stay; and mortality. Queries were directed to the randomized trial in-
vestigators for further information as needed.
Statistical Analysis
The between-group standardized mean differences for postoperative
blood loss and blood product transfusion were computed with 95% confi-
dence intervals (CIs). The standardized mean difference, the customary ef-
fect sizemeasure for continuous data inmeta-analysis, expresses difference
as a percentage of pooled standard deviation and is well-suited to postop-
erative blood loss and blood product transfusion data in cardiac surgery,
which can vary many fold in scale between trials. In contrast to blood
loss and blood product transfusion, other continuous variables did not dis-
play wide variability in scale between studies, and such data were analyzed
without standardization as mean differences in the originally reported units
of measurement. The relative risk (RR) of reoperation for bleeding and its
95% CI were also calculated. Heterogeneity was assessed by the Cochran
Q test and the I2 statistic. In the absence of significant heterogeneity, stan-
dardized mean difference and RRwere combined across trials under a fixed
effects model. Publication bias was evaluated by linear regression of stan-
dardized effect versus precision. Subgroup analyses were planned a priori
to compare the effects of different HES solutions. The significance of sub-
group differences was determined by test of interaction.
Role of Sponsor
The study sponsor played no role in the design of the study; in the col-
lection, analysis, and interpretation of data; in manuscript preparation; or in
the decision to submit for publication.
RESULTS
Included Trials
Eighteen randomized trials with 970 total patients re-
ported from 1982 to 2008 were included in the meta-
analysis (Figure 1).2-22 The attributes of the included
trials are summarized in Table 1. The median number of pa-
tients per trial was 48, with an interquartile range of 30 to
60. The indications for colloid use were volume expansion
in 9 of the trials, pump priming in 5, and both in 4.
Three trials were reported in 2 publications each.12,13,19-22
One trial15 was reported in abstract form only, and full
documentation of the trial design, data and statistical analy-
sis was secured from the US Office for Human Research
Protections. Another trial16 was unpublished, and the com-
plete study report submitted by an HESmanufacturer in sup-
port of a New Drug Application was obtained from the US
Food and Drug Administration. Unpublished individual
patient postoperative blood loss and blood product transfu-
sion data for 3 included trials were furnished by the investi-
gators on request.18-22
HES 450/0.7 was compared with albumin in 9 trials and
with HES 200/0.5 in 6. One of the 6 trials evaluating HES
200/0.5 also included a third study arm of 15 patients allo-
cated to receive HES 130/0.4.21,22 No other included trials
compared HES 130/0.4 with albumin, and consequently it
was not possible to combine results quantitatively across
trials of HES 130/0.4 versus albumin. Four trials,
including the trial with the third arm receiving HES 130/
0.4,21,22 compared HES 200/0.5 and HES 130.0.4 head toery c July 2012
FIGURE 1. Process of randomized trial selection. Appendices E1 and E2
provide reference citations for each report judged not eligible after screen-
ing and detailed examination, respectively, categorized by reason. HES,
Hydroxyethyl starch.
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Mhead. Of those 4 trials, 3 were manufacturer-sponsored in-
vestigations with an equivalence hypothesis.14,16,17 No
eligible head-to-head trials of HES 450/0.7 versus either
HES 200/0.5 or HES 130/0.4 were identified.
Saline solution was the only HES solvent tested in all tri-
als except 1. That trial compared HES 450/0.7 in balanced
electrolyte with HES 450/0.7 in saline solution and albu-
min.15 Mean chest tube drainage during the first 24 postop-
erative hours for the group receiving HES 450/0.7 in
balanced electrolyte (1355  961 mL) did not differ signif-
icantly (P ¼ .85) from that for recipients of HES 450/0.7 in
saline solution (1388  734 mL), and accordingly the data
for those two HES 450/0.7 groups were pooled for the meta-
analysis.
Bleeding
Among the included trials, mean postoperative blood loss
in the albumin group ranged 4-fold, from360mL to 1373mL
(Figure 2). The corresponding range among HES recipients
was 7-fold, from 217 mL to 1559 mL. Compared with albu-
min, HES increased postoperative bleeding by 33.3% of
a pooled SD (P< .001), as shown in Figure 2 (A). There
was no evidence of heterogeneity (P ¼ .40) or publication
bias (P ¼ .67). For the 4 more contemporary trials reportedThe Journal of Thoracic and Caafter 2000, the pooled increase in postoperative blood loss
(49.7%; 95% CI, 23.0%–76.5%) among patients exposed
to HES was greater than that in the 11 earlier trials from
1982 through 2000 (25.6%; 95% CI, 7.4%–43.8%); how-
ever, this differencewas not statistically significant (P¼ .14).
The postoperative blood loss increases among patients re-
ceivingHES 450/0.7 (36.2%) andHES 200/0.5 (28.5%) did
not differ significantly (P¼ .62). In 4 head-to-head random-
ized trials (Figure 2, B), there was no significant difference
in postoperative blood loss (P ¼ .21) between patients
receiving HES 130/0.4 and those receiving HES 200/0.5.
Reoperation
Data on reoperations for bleeding were available from 15
of the 18 included trials. In 5 of the 15 trials with such data,
no patients underwent reoperation for bleeding. The RR of
reoperation for bleeding thus could be computed for 10 total
trials.
As shown in Figure 3, A, the risk of reoperation for bleed-
ing was more than doubled by HES (RR, 2.24; P ¼ .020).
Relative to albumin, the risk for HES 450/0.7 (RR, 2.13)
did not differ significantly (P ¼ .87) from that for HES
200/0.5 (RR, 2.38). In head-to-head comparisons of HES
200/0.5 relative to HES 130/0.4 (Figure 3, B), no difference
in risk of reoperation for bleeding was detectable (RR, 0.77;
P ¼ .62).
Blood Products
Data were available for postoperative transfusion of
RBCs in 14 of the 18 included trials, for transfusion of
FFPs in 10 trials, and for transfusion of platelets in 9. Dif-
ferences in trials with nonzero use of a particular blood
product type are summarized in Table 2. Relative to albu-
min (Table 2), HES increased the transfusion of RBCs by
28.4% of a pooled SD (P < .001), of FFP by 30.6%
(P ¼ .008), and of platelets by 29.8% (P ¼ .027). Between
HES 450/0.7 and HES 200/0.5, no significant differences
were evident for the increases in RBC (P ¼ .36), FFP
(P ¼ .47), and platelet (P ¼ .74) transfusions. In the 2
head-to-head trials with available blood product transfusion
data (Table 2), no differences were found between HES
130/0.4 and HES 200/0.5 in transfusion of RBCs
(P ¼ .24), FFP (P ¼ .70), or platelets (P ¼ .46).
Fluid Balance
Data for cumulative fluid balance during the first 24 hours
after surgery were available for 6 trials comparing HESwith
albumin. No significant differences were found (Table E1).
Hemodynamics
Tables E1 and E2 present analyses of hemodynamics at
24 hours after surgery for trials with such data reported.
In patients receiving HES, heart rate was lower on
average by 3.2 beats/min, cardiac index was lower byrdiovascular Surgery c Volume 144, Number 1 225
TABLE 1. Included trials
Trial n
Age
(y, mean) Indication Surgery Colloid regimen
Diehl et al, 19822 60 57.4 VE CABG 5% albumin vs 6% HES 450/0.7
in first 24 h
Moggio et al, 19833 47 56.6 VE 35 CABG, 9 valve,
3 CABG and valve
5% albumin vs 6% HES 450/0.7
to postoperative cardiac index
and PWP targets
Saunders et al, 19834 20 60.7 PP CABG 2.5% albumin vs 3% HES 450/0.7
asanguineous prime
Kirklin et al, 19845 30 — VE CABG 5% albumin vs 6% HES 450/0.7
over 24 h to maintain 6-12 mm Hg
left atrial pressure and
>2.0 L $ min1 $ m2 cardiac index
Gallagher et al, 19856 10 53.9 VE CABG 5% albumin vs 6% HES 450/0.7 to
maintain 12–18 mm Hg postoperative PWP
Sade et al, 19857 54 54 PP CABG, valve, CABG and valve 0.9% albumin vs 1.0% HES 450/0.7 prime
London et al, 19898 94 63 VE 71 primary and 3 repeat CABG,
12 primary and 4 repeat valve,
8 CABG and valve
5% albumin vs 10% HES 200/0.5 in first
24 h to maintain 2.0 L $ min1 $ m2
cardiac index and mean arterial
pressure 10% of baseline
London et al, 19929 60 60 PP 56 CABG, 4 valve 3.8% albumin vs 3.8% HES 200/0.5 prime
Mastroianni et al, 199410 34 60.1 VE 27 CABG, 2 valve 5% albumin vs 10% HES 200/0.5 in first
24 h to maintain>2.0 L $ min1 $ m2
cardiac index, 100 mm Hg systolic
blood pressure and 20 mm Hg PWP
Saxena et al, 199711 50 53 VE CABG 5% albumin vs 6% HES 450/0.7
intraoperatively to replace 10 mL $ kg1
withdrawn blood
Tigchelaar et al, 199712,13 22 60.7 PP CABG 4% albumin vs 2.5% HES 200/0.5 prime
Gallandat Huet et al, 200014 59 62.3 VE and PP CABG Priming and perioperative volume
expansion with 6% HES 130/0.4 vs
6% HES 200/0.5; 1000 mL of respective
study HES solutions in prime (total prime
volume unreported)
Bennett-Guerrero
et al, 200115
147 67.1 VE and PP Primary CABG, valve,
CABG and valve
Priming and intraoperative volume expansion
with 5% albumin vs 6% HES 450/0.7
in normal saline solution vs 6% HES
450/0.7 in Ringer’s lactate solution;
2.5%, 3% and 3% final prime
concentrations, respectively
Frey, 200116 61 62.1 VE and PP Primary CABG Priming and perioperative volume expansion
with 6% HES 130/0.4 vs 6% HES 200/0.5;
500 mL of respective study HES solutions
in prime (total prime volume unreported)
Kasper et al, 200017 117 62.3 VE and PP Elective primary CABG Priming and perioperative volume expansion
with 6% HES 130/0.4 vs 6% HES 200/0.5;
3% final prime concentration of study
HES solution in both groups
Kuitunen et al, 200418 30 58 PP Elective primary CABG Priming with 20 mL $ kg1 4% albumin vs
6% HES 450/0.7, respectively, 3.4 and
4.9% final concentrations
Niemi et al, 200619,20 30 62.5 VE 29 CABG, 11 aortic valve,
5 mitral valve
15 mL $ kg1 4% albumin vs 6%
HES 200/0.5 in ICU
Niemi et al, 200821,22 45 61 VE 14 CABG, 18 aortic valve,
5 mitral valve, 2 CABG
and aortic valve, 6 composite
15 mL $ kg1 4% albumin vs 6% HES
130/0.4 vs 6% HES 200/0.5 in ICU
CABG, Coronary artery bypass grafting; HES, hydroxyethyl starch; ICU, intensive care unit; PP, pump priming; PWP, pulmonary wedge pressure; VE, volume expansion.
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FIGURE 2. A and B, Postoperative blood loss. Error bars indicate 95% CI. Data points are scaled in proportion to meta-analytic weight. CI, 95% Con-
fidence interval; HES, hydroxyethyl starch; SMD, standardized mean difference; SD, standard deviation.
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M0.17 L $min1 $m2, and central venous pressure was lower
by 0.97 mm Hg. These differences were statistically
significant. No corresponding differences were observedThe Journal of Thoracic and Cain mean arterial pressure or pulmonary capillary wedge
pressure. No hemodynamic differences could be demon-
strated between HES 130/0.4 and HES 200/0.5.rdiovascular Surgery c Volume 144, Number 1 227
FIGURE 3. A and B, Reoperations for bleeding. Graphic conventions are as given in Figure 2. CI, 95% Confidence interval; HES, hydroxyethyl starch.
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MOther Outcomes
Time on ventilator did not differ significantly between
HES and albumin in 5 trials with data for this end point
(Table E3). There was also no overall difference in ICU
stay. Although there was evidence from a subgroup
analysis that HES 200/0.5 significantly prolonged ICU
stay relative to albumin by half a day, that result was
derived from just 2 trials and hence should be viewed
with caution. No differences in either time on ventilator
or ICU stay were found between HES 130/0.4 and HES
200/0.5.
Mortality data were available from 11 of the 18 included
trials. No deaths occurred in 6 of those 11 trials. In the re-
maining 5 trials with mortality data, a total of 12 patients
died: 9 in trials comparing HES with albumin and 3 in
head-to-head trials of HES 130/0.4 and HES 200/0.5.228 The Journal of Thoracic and Cardiovascular SurgWith only 12 total events, no mortality differences were
detectable (Table E3).
DISCUSSION
This meta-analysis confirms the finding of a 2001 meta-
analysis1 of increased blood loss after CPB among patients
receiving HES compared with albumin. In contrast to the
previous meta-analysis and to any individual randomized
trial, this meta-analysis shows for the first time that the in-
crease in blood loss is also accompanied by more frequent
reoperation for bleeding and greater blood product transfu-
sion. Additionally, the effects of HES did not differ detect-
ably in relation to molecular weight and substitution.
Although differences between HES solutions were not
found in a number of individual trials, the statistical power
to detect differences in those trials was limited. Thisery c July 2012
TABLE 2. Blood product transfusion
Colloids compared Red blood cells Fresh-frozen plasma Platelets
HES 450/0.7 vs albumin 34.0% (13.8%–54.1%); 8 trials 25.6% (0.6% to 51.8%); 4 trials 32.5% (1.7%–63.2%); 2 trials
HES 200/0.5 vs albumin 18.1% (9.3% to 45.4%); 5 trials 44.6% (0.6%–88.5%); 3 trials 22.4% (28.6% to 73.5%); 2 trials
Total 28.4% (12.2%–44.6%); 13 trials 30.6% (8.0%–53.1%); 7 trials 29.8% (3.4%–56.2%); 4 trials
I2 (95% confidence interval) 11% (0%–49%); P ¼ .34 8% (0%–73%); P ¼ .37 0% (0%–72%); P ¼ .66
P for HES 450/0.7
vs HES 200/0.5
.36 .47 .74
HES 130/0.4 vs HES 200/0.5 24.9% (16.8% to 66.6%); 2 trials 8.2% (33.5% to 49.9%); 2 trials 15.8% (25.8% to 57.5%); 2 trials
I2 0%; P ¼ .75 0%; P ¼ .33 0%; P ¼ .86
Data represent pooled standardized mean difference with 95% confidence interval except as marked. HES, Hydroxyethyl starch.
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from the combined statistical power of 18 randomized tri-
als, that increased bleeding, reoperation, and transfusion ap-
pear to be generic effects of HES solutions irrespective of
molecular weight and substitution.
In the evaluation of HES, albumin is the most appropriate
control fluid, because it is the colloid normally present in
circulation and is free of adverse effects on coagulation.
The safety of HES solutions, including their impact on
bleeding, has often been claimed on the basis of compari-
sons with other artificial colloids. That approach is un-
sound, because the control artificial colloid may itself
exert adverse effects, such as impairment of coagulation.
From examination of head-to-head trials, this meta-
analysis confirms the equivalence of HES 130/0.4 and
HES 200/0.5; accordingly, the demonstrated adverse effects
of HES 200/0.5 relative with albumin do not provide reas-
surance of a favorable safety profile for HES 130/0.4. In
this context, there is a need for randomized trials directly
comparing HES 130.0.4 with albumin in cardiac surgery.
One such trial is currently ongoing (ClinicalTrials.gov iden-
tifier NCT01174719), and another has been announced
(ClinicalTrials.gov identifier NCT01418521).
Among the trials included in this meta-analysis, patient
enrollment criteria, fluid protocols, transfusion targets, and
other aspects of clinical management strategywere not stan-
dardized. Nonetheless, differences in patient characteristics
and treatment are unlikely to have confounded the conclu-
sions of the meta-analysis for 2 reasons. First, the meta-
analysis was restricted to randomized, controlled trials,
and therefore extraneous factors other than type of colloid
administered should not have generated any systematic
bias. Second, if patient and treatment differences between
trials were important determinants of outcome, then it
should have been possible to detect heterogeneity; however,
there was no evidence of heterogeneity in blood loss, reop-
eration for bleeding, or blood product transfusion. Another
limitation of the meta-analysis was the inadequate available
data comparing HES 130/0.4 directly with albumin.
To avoid potential sampling bias, a comprehensive sys-
tematic search strategy for eligible trials was implemented.The Journal of Thoracic and CaThe strategy used multiple search methods and was de-
signed to ensure, to the maximum extent possible, that the
totality of relevant evidence was assembled for the meta-
analysis. Prespecified trial eligibility criteria were adopted,
and no ad hoc exclusions of trials were made whatsoever, to
eliminate any selection bias. Finally, as a safeguard against
possible publication bias, unpublished trial data were
sought and secured.
Multiple mechanisms may explain the detrimental im-
pact of HES on hemostasis after surgery with CPB, includ-
ing depletion of circulating coagulation factors, impairment
of platelet function, reduction in clot strength, and enhance-
ment of fibrinolysis.22,23 In 2 of the randomized trials
included in the meta-analysis,18,22 HES solutions were
shown by thromboelastography to decrease maximum clot
firmness in patients undergoing CPB. In 1 of those trials,
the magnitude of the deleterious effect was closely similar
between HES 130/0.4 and HES 200/0.5.22
One major potential advantage of HES relative to albu-
min is its lower unit acquisition cost. On the other hand,
in a retrospective case-control study of 288 patients, substi-
tution of HES for albumin as the extracorporeal circuit
priming fluid was associated with a dose-dependent in-
crease in hemorrhage, and the added costs to treat hemor-
rhage were greater than the savings afforded by the lower
acquisition cost ofHES.24 Another advantage ofHES, a syn-
thetic colloid, is more consistent supply. As a plasma-
derived colloid, albumin is subject to periodic shortages.
The in vitro colloid osmotic pressure of available 6% to
10% HES solutions is higher than that of the 4% to 5% al-
bumin solutions investigated for volume expansion in sur-
gery with CPB (Table 1). Additionally, in the majority of
trials included in the meta-analysis dealing with pump
priming, higher final concentrations of HES than albumin
were used. Thus the HES solutions infused for volume ex-
pansion or incorporated in the extracorporeal circuit prime
may have been capable of exerting higher oncotic forces
in vivo that might potentially reduce interstitial fluid accu-
mulation. Nevertheless, no significant difference was de-
tected between HES and albumin in cumulative fluid
balance during first 24 hours after surgery (Table E1).rdiovascular Surgery c Volume 144, Number 1 229
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may contribute to poorer survival after surgery with CPB.
Exposure to artificial colloids, predominantly HES, was
an independent risk factor for death in a retrospective hos-
pital discharge database study of 548 deaths among 19,578
cardiac surgical patients, with an adjusted odds ratio of 1.25
(95% CI, 1.04–1.49).25
CONCLUSIONS
HES was found to increase postoperative bleeding, reop-
eration for bleeding, and blood product transfusion after
CPB in this meta-analysis of randomized trials. Differences
in safety profile related tomolecular weight and substitution
were not apparent. These results support an evidence-based
recommendation for the avoidance or cautious use of HES
solutions in patients undergoing surgery with CPB.
We gratefully acknowledge the cooperation of Sandeep Chau-
han, MD, Anne Kuitunen, MD, PhD, Tomi Niemi, MD, Young
Lan Kwak, MD, PhD, Alexey Schramko, MD, PhD, and Willem
van Oeveren, PhD, in furnishing supplementary data from their
trials.
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APPENDIX E1. Reports Judged Not Eligible After
Screening
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numbers 8–10 under ‘‘Boldt and Colleagues Study’’).
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TABLE E1. Fluid balance, heart rate, and cardiac index
Colloids compared Fluid balance (mL) Heart rate (beats/min) Cardiac index (L $ min1 $ m2)
HES 450/0.7 vs albumin 212 (361 to 785); 2 trials —* 0.06 (0.38 to 0.25); 3 trials
HES 200/0.5 vs albumin 105 (621 to 411); 4 trials 2.3 (5.5 to 0.8); 5 trials 0.14 (0.26 to0.03); 5 trials
Total 37 (347 to 420); 6 trials 3.2 (6.0 to0.5); 6 trials 0.17 (0.24 to0.11); 8 trials
I2 (95% confidence interval) 8% (0%–77%); P ¼ .36 52% (0%–81%); P ¼ .07 0% (0%–60%); P ¼ .58
P for HES 450/0.7 vs HES 200/0.5 .42 .26 .49
HES 130/0.4 vs HES 200/0.5 —* 2.7 (7.6 to 2.3); 2 trials 0.00 (0.07 to 0.07); 2 trials
I2 —* 14%; P ¼ .28 0%; P  .999
Cumulative fluid balance during first 24 hours after surgery and heart rate and cardiac index at 24 hours after surgery. Mean difference computed as value for hydroxyethyl starch
minus albumin and hydroxyethyl starch 130/0.4 minus hydroxyethyl starch 200/0.5. Data represent pooled mean differencewith 95% confidence interval except as marked.HES,
Hydroxyethyl starch. *Only 1 trial in this category with data for this end point.
TABLE E2. Mean arterial pressure, central venous pressure, and pulmonary capillary wedge pressure
Colloids compared MAP (mm Hg) CVP (mm Hg) PCWP (mm Hg)
HES 450/0.7 vs albumin —* —* —y
HES 200/0.5 vs albumin 2.9 (6.3 to 0.4); 4 trials 0.97 (1.82 to0.12); 5 trials 0.39 (1.36 to 0.58); 5 trials
Total 2.9 (6.3 to 0.4); 4 trials 0.97 (1.82 to0.12); 5 trials 0.33 (1.26 to 0.59); 6 trials
I2 (95% confidence interval) 0% (0%–83%); P ¼ .43 0% (0%–28%); P ¼ .88 0% (0%–64%); P ¼ .62
P for HES 450/0.7 vs HES 200/0.5 — — .71
HES 130/0.4 vs HES 200/0.5 1.4 (6.6 to 3.8); 2 trials 0.05 (1.28 to 1.18); 2 trials 0.59 (0.87 to 2.04); 2 trials
I2 0%; P ¼ .84 0%; P ¼ .81 0%; P ¼ .70
Values obtained 24 hours after surgery. Mean difference computed as value for hydroxyethyl starch minus albumin and hydroxyethyl starch 130/0.4 minus hydroxyethyl starch
200/0.5. Data represent pooled mean difference with 95% confidence interval except as marked. CVP, Central venous pressure; HES, hydroxyethyl starch; MAP, mean arterial
pressure;PCWP, pulmonary capillary wedge pressure. *No trials in this category with data for this end point. yOnly 1 trial in this category with data for pulmonary capillary wedge
pressure.
TABLE E3. Time on ventilator, intensive care unit stay, and mortality
Colloids compared Ventilator time (h) ICU stay (d) Mortality
HES 450/0.7 vs albumin 0.79 (0.21 to 1.80); 3 trials 0.04 (0.17 to 0.09); 5 trials —*
HES 200/0.5 vs albumin 0.86 (2.74 to 4.46); 2 trials 0.51 (0.05–0.96); 2 trials 0.71 (0.16–3.12); 2 trials
Total 0.80 (0.17 to 1.76); 5 trials 0.00 (0.12 to 0.12); 7 trials 0.99 (0.27–3.57); 3 trials
I2 (95% confidence interval) 37% (0%–77%); P ¼ .17 36% (0%–73%); P ¼ .16 0% (0%–87%); P ¼ .45
P for HES 450/0.7 vs HES 200/0.5 .97 .024 .43
HES 130/0.4 vs HES 200/0.5 0.02 (1.93 to 1.89); 2 trials 0.08 (0.32 to 0.16); 3 trials 0.59 (0.08–4.34); 2 trials
I2 (95% confidence interval) 0% (—); P ¼ .95 0% (0%–76%); P ¼ .65 0% (—); P ¼ .60
Mean difference computed as value for hydroxyethyl starch minus albumin and hydroxyethyl starch 130/0.4 minus hydroxyethyl starch 200/0.5. Relative risk computed as value
for hydroxyethyl starch divided by albumin and hydroxyethyl starch 130/0.4 divided by hydroxyethyl starch 200/0.5. Data represent pooled mean difference (pooled relative risk
for mortality, not estimable for trials with 0 deaths in both groups) with 95% confidence interval except as marked. HES, Hydroxyethyl starch; ICU, intensive care unit. *Only 1
trial in this category with mortality data.
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